BioSpace News Archive

The tested intranasal formulation employs Mucodel’s Co-Gel platform for the mucosal delivery of pharmaceutically active agents.

If approved, would be the first treatment for deadly smallpox.

The results (abstract 1477) were presented on Sunday, December 10, 2017 at the 59th ASH Annual Meeting in Atlanta.

ILUVIEN 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

The new website has a clean, uncluttered design, improved functionality, and enhanced rich content to provide both healthcare professionals and patients with essential information about the NOVOCART 3D Phase 3 clinical trial.

A look at BioPorto’s financial calendar for 2018.

These are the first studies to investigate ONCOS-102 in combination with other drugs.

The primary endpoint of the study, a 10% improvement in overall survival of the Multikine treatment regimen plus Standard of Care (SOC) vs. Standard of Care alone, will be determined after a total of 298 deaths have occurred in these two main comparator arms of the study and have been recorded in the study database.

The CMML study is one of four ongoing company-sponsored Phase 2 studies of tipifarnib.

These data were presented at the 59th American Society of Hematology (ASH) Annual meeting in Atlanta, Georgia on Sunday, December 10, 2017.